论文部分内容阅读
目的研究表皮生长因子受体(EGFR)对食管癌患者放化疗敏感性的预测作用。方法收集35例初治食管癌患者的病理组织,应用免疫组化SP法检测EGFR的表达情况,按是否存在EGFR过表达将所有患者分为2组,同时回顾性分析入组患者的同步放化疗效果,比较两组间的疗效差异。结果 EGFR阳性组与阴性组的同步放化疗完全缓解(CR)率分别为57.7%(15/26)以及11.1%(1/9),两组间差异有统计学意义(P=0.022)。结论EGFR可能有助于预测食管癌的同步放化疗敏感性。
Objective To study the predictive value of epidermal growth factor receptor (EGFR) on the chemosensitivity of esophageal cancer patients. Methods The pathological tissues of 35 newly diagnosed esophageal cancer patients were collected. The expression of EGFR was detected by immunohistochemical SP method. All patients were divided into two groups according to the presence or absence of EGFR overexpression. Simultaneous retrospective analysis of concurrent chemoradiation Effect, the difference between the two groups efficacy. Results The rate of complete remission (CR) of concurrent radiotherapy and chemotherapy was 57.7% (15/26) and 11.1% (1/9) respectively in EGFR positive group and negative group. The difference was statistically significant (P = 0.022). Conclusion EGFR may be useful in predicting the chemoradiation sensitivity of esophageal cancer.